1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

ESMO 23: Opdivo Matches Keytruda In Perioperative Lung Cancer

 
• By Elizabeth Cairns

Bristol Myers Squibb’s PD-1 looks set to follow Merck & Co’s rival in a new lung cancer setting but might second place be the first loser?    

Group of surgeons doing surgery in hospital operating theater. Medical team doing critical operation. -

A success – and a pretty good one. New data on Opdivo revealed in a late-breaking abstract released early at this weekend’s European Society for Medical Oncology (ESMO) meeting in Madrid, suggests that Bristol Myers Squibb Company’s checkpoint inhibitor might be a serious rival to Merck & Co., Inc.’s powerhouse Keytruda.

Key Takeaways
  • Opdivo cuts the risk of progression, recurrence or death by 42% when used perioperatively for non-small cell lung cancer

The setting is perioperative non-small cell lung cancer (NSCLC), in which a drug, plus chemotherapy, is given both before and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 
• By Anju Ghangurde

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.

Four Chinese Firms Snag Global First-In-Class Approvals In China

 
• By Dexter Jie Yan

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 
• By Alaric DeArment

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 
• By Andrew McConaghie

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.

More from Therapy Areas

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 
• By Alaric DeArment

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By Kevin Grogan

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 
• By Andrew McConaghie

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.